Compare Inovio Pharmaceuticals Inc (INO) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Schwab US Large Cap Growth ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while Schwab US Large Cap Growth ETF trades at $35.63. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SCHG | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Sector/Thematic |
52-Week High | $2.87 | $35.83 |
52-Week Low | $0.66 | $28.10 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
SCHG trades at $35.61, down 0.61% today, with a bullish technical trend supported by moving averages but neutral oscillators. The ETF focuses on U.S. large-cap growth stocks, benefiting from AI and technology themes, though key financial ratios are not disclosed in the provided data. Recent news highlights its low 0.04% expense ratio and strong historical performance, with institutional activity showing mixed positions.
Outlook remains positive due to exposure to growth sectors like AI, but risks include high concentration in top holdings and sensitivity to interest rates. Analyst sentiment is generally favorable, emphasizing long-term growth potential despite valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
